Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer

ObjectiveSeveral trials have shown that pembrolizumab plus chemotherapy was more effective in patients with advanced non-small-cell lung cancer (NSCLC) than chemotherapy monotherapy. However, whether pembrolizumab plus chemotherapy is still a better choice for first-line treatment in elderly patient...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Zhengyu Yang, Ya Chen, Yanan Wang, Minjuan Hu, Fangfei Qian, Yanwei Zhang, Bo Zhang, Wei Zhang, Baohui Han
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Frontiers Media S.A. 2022-02-01
سلاسل:	Frontiers in Immunology
الموضوعات:	pembrolizumab chemotherapy – oncology non-small-cell lung cancer first line therapy elderly patients
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.807575/full
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!